NCT02661152CompletedPhase 3
DAHANCA 30: A Randomized Non-inferiority Trial of Hypoxia-profile Guided Hypoxic Modification of Radiotherapy of HNSCC.
DAHANCA 30: A Randomized Non-inferiority Trial of Hypoxia-profile Guided Hypoxic Modification With Nimorazole During Radiotherapy/Chemoradiotherapy of Squamous Cell Carcinoma of the Head and Neck.
Source: ClinicalTrials.gov · Last updated 2 Nov 2026
Brief summary (registry, in English)
Hypoxic modification of radiotherapy with nimorazole has previously been shown to increase radiosensitivity in hypoxic head and neck squamous cell carcinomas (HNSCC). In Denmark, nimorazole is added the radiotherapy of most HNSCC, as it has not previously been possible to discriminate more hypoxic tumours from less hypoxic tumours. A hypoxia gene profile has shown to discriminate between responders and non-responders to nimorazole. In DAHANCA 30, expected hypoxia profile guided non-responders are randomized to +/- nimorazole during radiotherapy.This in order to verify clinical use of the gene profile in selecting the relevant patients for hypoxic modification of radiotherapy with nimorazole.
- Status (registry)
- Completed
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 1252 (estimated)
- First submitted
- 14 Jan 2016
- Start date
- Sept 2016
- Primary completion date
- Dec 2024
- Lead sponsor
- Danish Head and Neck Cancer Group
- Diseases
- Head and neck cancer
- NCT number
- NCT02661152
- EU CT number
- 2024-516178-31-00
- EudraCT number
- 2015-004133-27
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 1252
- From Sept 2016 to the primary completion date, Dec 2024
- 9 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous or present malignant disease conflicting with the radiotherapy treatment or evaluation of the treatment.
- Initiation of radiotherapy more than 3 weeks after inclusion
Other
- Participation in a conflicting protocol.
Who the study is looking for
- Head and neck squamous cell carcinoma with indication for hypoxic modification with nimorazole in accordance to the Danish Head and Neck Cancer guidelines (DAHANCA guidelines).
- Informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (9)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Region Nordjylland Coordinator of this site? Confirm its status | Aalborg | Denmark | Active, not recruiting |
| Region Midtjylland Coordinator of this site? Confirm its status | Aarhus N | Denmark | Active, not recruiting |
| Rigshospitalet Coordinator of this site? Confirm its status | Copenhagen Oe | Denmark | Active, not recruiting |
| Region Hovedstaden Coordinator of this site? Confirm its status | Herlev | Denmark | Active, not recruiting |
| Næstved Hospital Coordinator of this site? Confirm its status | Næstved | Denmark | Active, not recruiting |
| Region Syddanmark Coordinator of this site? Confirm its status | Odense C | Denmark | Active, not recruiting |
| Helse Bergen HF Coordinator of this site? Confirm its status | Bergen | Norway | Active, not recruiting |
| Oslo University Hospital HF Coordinator of this site? Confirm its status | Oslo | Norway | Active, not recruiting |
| St. Olavs hospital HF Coordinator of this site? Confirm its status | Trondheim | Norway | Active, not recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.